|Bid||89.14 x 800|
|Ask||90.21 x 1300|
|Day's Range||88.50 - 91.35|
|52 Week Range||74.31 - 128.94|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
Today we will run through one way of estimating the intrinsic value of United Therapeutics Corporation (NASDAQ:UTHR...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
United Therapeutics Corporation (NASDAQ: UTHR ) may face stiffening competition from generic entrants, which could meaningfully increase pricing pressure and shrink its market share, according to Bank ...
Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial
United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.63% and 19.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you're interested in United Therapeutics Corporation (NASDAQ:UTHR), then you might want to consider its beta (a...
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Thanks to the Dodd-Frank Act passed back in 2008, we now have some new information in the annual reports public companies are required to file: how the CEO's compensation compares to that of rank-and-file employees. Some public companies are outright exempt for the reporting rule, including: companies with revenue of less than $1 billion up to five years after an initial public offering, smaller reporting companies (defined as having less than $75 million worth of stock stock that isn't held by management or major investors) and foreign private issuers.
The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to...
MannKind Corp (MNKD) reported financial results for their second quarter ending June 30th and provided a business update. Both gross and net product sales set new records, as did product margin. As a reminder, Afrezza is sold in 4-,8- and 12-unit cartridges.
Martine Rothblatt became the CEO of United Therapeutics Corporation (NASDAQ:UTHR) in 2016. First, this article will...